ESR2 and prostate carcinoma: Although ERβ clearly downregulates MYC in prostate cancer cell lines24 and MYC promoter contains consensus ZFHX3 binding sites50, our findings for the first time demonstrate that MYC transcription is indeed repressed by ZFHX3 in prostate cancer cells.